ClinicalTrials.gg
Active, not recruitingNCT04838496MEND-ITUpdated Oct 23, 2026

Induction Chemotherapy for Locally Advanced Rectal Cancer

A Phase 2 interventional study of FOLFOXIRI Protocol in Rectal Cancer, sponsored by Catharina Ziekenhuis Eindhoven. Active, not recruiting at 13 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Catharina Ziekenhuis Eindhoven · Phase 2, Interventional, and Treatment

How we know

Updated Oct 23, 2026Now Active, not recruitingStart date moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
128
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 74 studies in Rectal Neoplasms with a site in Netherlands — 21 open to participants now, 32 under way, 8 of them phase 3. Rectal Neoplasms · Netherlands.

Planned enrollment
24th of 59
128 · median 108
Started
2021
with 3 others
Phase 2
13 of 74
2 open now
Primary completion
2026-08
later than 14 of 31 live
Registered
52nd of 74
by date

Among the 74 studies in Rectal Neoplasms with a site in Netherlands, this one is the 24th largest by planned enrollment of the 59 interventional ones that give a count, is one of 4 that started in 2021, is one of 13 in phase 2, reaches primary completion later than 14 of the 31 other live ones, and was the 52nd registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

21 of the 74 studies in Rectal Neoplasms with a site in Netherlands are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 74 studies in Rectal Neoplasms with a site in Netherlands, or all of them as a file.
02

Study summary

Despite developments in the multidisciplinary treatment of patients with locally advanced rectal cancer (LARC), such as the introduction of total mesorectal excision (TME) by Heald et al. and the shift from adjuvant to neoadjuvant (chemo)radiotherapy ((C)RT), local and distant recurrence rates remain between 5-10% and 25-40% respectively. Several studies established tumour characteristics with particularly bad prognosis; it was demonstrated that the occurrence of mesorectal fascia involvement (MRF+), grade 4 extramural venous invasion (EMVI), tumour deposits (TD) and enlarged lateral lymph nodes (LLN) lead to high local and distant recurrence rates and decreased survival when compared with LARC without these particularly negative prognostic factors. This type of LARC is described as high risk LARC (hr-LARC). Achieving a resection with clear resection margins (R0) is an important prognostic factor for local (LR) and distant recurrence (DM) as well as survival. With the aim to further reduce the risk of recurrent rectal cancer, to diminish distant metastasis and to improve overall survival for patients with LARC, induction chemotherapy (ICT) became a growing area of research. The addition of ICT has the ability to induce more local tumour downstaging, possibly leading to resectability of previously unresectable tumours, more R0 resections and less extensive surgery. In the case of a complete clinical response, surgery may even be omitted. ICT may also have the potential to eradicate micrometastases. Hence, increased local downstaging and reducing distant metastatic spread may reduce LR and DM rates and improve survival and quality of life. In recent years, the use of ICT was investigated and showed promising results, but little is known about the addition of ICT in patients with high risk LARC. Since these patients have a particularly bad prognosis, both with regard to locoregional and distant failure, a more intensified neoadjuvant treatment with FOLFOXIRI is anticipated to improve short- and long term results.

03

Conditions studied

  • Rectal Cancer

Browse trials for

Keywords

  • Locally advanced rectal cancer
  • Induction chemotherapy
  • Neoadjuvant chemotherapy
  • Chemoradiotherapy
04

Who can participate

The criteria were revised on the registry on Oct 23, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • WHO performance score 0-1.
  • Fit for (modified dose) triple chemotherapy (FOLFOXIRI)
  • Histopathologically confirmed rectal cancer.
  • Lower border of the tumour located on or below the sigmoidal take-off as established on MRI of the pelvis.
  • Confirmed high-risk locally advanced rectal cancer, at high risk of treatment failure, meeting one of the following imaging based criteria:

    • Tumour invasion of mesorectal fascia (MRF+)
    • The presence of grade 4 extramural venous invasion (mrEMVI)
    • The presence of tumour deposits (TD)
    • The presence of bilateral extramesorectal lymph nodes with a short-axis size ≥ 7mm (LLN) or extensive LLN involving pelvic side wall structures, at high risk of an incomplete resection.
  • Resectable disease as determined on magnetic resonance imaging (MRI) or deemed resectable disease after treatment.

Expected gross incomplete resection with overt tumour remaining in the patient after resection, tumour invasion in the neuroforamina, encasement of the ischiadic nerve and invasion of the cortex from S2 and upwards are considered not resectable • Written .

Exclusion criteria

Exclusion Criteria:

  • Evidence of disease at the moment of inclusion or within six months prior to inclusion except for patients with enlarged iliac or inguinal lymph nodes and aspecific lung noduli.
  • Homozygous DPD (Dihydropyrimidine dehydrogenase) deficiency.
  • Any chemotherapy within the past 6 months.

    o Any for the planned systemic therapy (e.g. severe allergy, pregnancy, kidney dysfunction and thrombocytopenia), as determined by the medical oncologist.

  • Previous radiotherapy in the pelvic area precluding chemoradiotherapy with a dose of 50 - 50.4 Gy.
  • Any contraindication for the planned chemoradiotherapy (e.g. severe allergy to the chemotherapy agent or no possibility to receive radiotherapy), as determined by the medical oncologist and/or radiation oncologist.
  • Any contraindication to undergo surgery, as determined by the surgeon and/or anaesthesiologist.
  • Concurrent that interfere with the planned study treatment or the prognosis of the resected tumour.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Single-arm study

    All patients will receive induction chemotherapy consisting of 4-6 cycles of FOLFOXIRI. Restaging will be performed after 4 cycles with a pelvic MRI and a thoraco-abdominal CT-scan. In case of stable or responsive disease, the remaining 2 cycles of FOLFOXIRI will be provided. In case of progressive, but still resectable disease, chemoradiation will be provided immediately, without the remaining 2 cycles of FOLFOXIRI. Restaging will be performed after chemoradiation. In case of resectable disease, surgery is performed.

    Drug: FOLFOXIRI Protocol

Interventions

  • FOLFOXIRI consists of oxaliplatin, irinotecan, leucovorin and 5-fluorouracil and is administered every 2 weeks: Dosing: * Day 1: irinotecan 165 mg/m2 body-surface area (BSA) intravenously (IV), followed by oxaliplatin 85mg/m2 BSA IV in combination with leucovorin 400mg/m2 BSA, followed by: * Day 1-2: 3200 mg/m2 BSA of continuous 5-fluorouracil IV * Day 3-14: rest days. Both regimen are initially administered for four cycles. In case of responsive or stable disease, a 5th and 6th cycle of FOLFOXIRI will be administered. In case of unacceptable toxicity, the aforementioned dosages can be reduced or one or more chemotherapeutical agents can be omitted at discretion of the medical oncologist and will be noted in the patient's medical file. At discretion of the medical oncologist, a start dosage of 75% of the advised dosage could be considered in patients above 70 years of age.

06

What researchers measure

Primary outcomes

  1. The main study parameter is the proportion of patients with a pathological complete response (pCR) and those patients who started a wait and see strategy and have sustained clinical complete response (cCR) at 1 year.

    The pCR is evaluated by an experienced pathologist. A pCR is defined as the absence of residual tumour cells in the complete resected specimen including all resected regional lymph nodes (ypT0N0). A cCR is defined as the absence of viable tumour tissue based on MRI, evaluated by an experienced radiologist. There is a cCR in case of a sustained clinical response at 1 year after chemoradiotherapy.

    Time frame: pCR is determined after surgery directly. There is a cCR in case of a sustained clinical response until at least one year after chemoradiotherapy

Secondary outcomes

  1. 3-year and 5-year local recurrence free survival.

    ocal recurrence is confirmed by either radiological or histopathological examination. A recurrence is registered by the treating physician in the patient's medical file.

    Time frame: 3 and 5 year

  2. 3-year and 5-year distant metastasis free survival.

    Distant metastases may be confirmed by either radiological or histopathological examination. Data on distant metastases are registered by the treating physician in the patient's medical file.

    Time frame: 3 and 5 year

  3. 3-year and 5-year progression free survival.

    Progression is defined as progression of the primary tumour, local recurrence, distant metastases confirmed by radiological or histopathological examination or death. Data regarding disease progression are registered by the treating physician in the patient's medical file.

    Time frame: 3 and 5 year

  4. 3-year and 5-year disease free survival.

    Disease free survival is defined as no confirmed recurrence, distant metastases or death. Disease recurrence is registered by the treating physician in the patient's medical file.

    Time frame: 3 and 5 year

  5. 3-year and 5-year overall survival.

    Mortality is registered in the patient's medical file which is linked to the municipal personal records database.

    Time frame: 3 and 5 year

  6. Radiological response after induction therapy.

    Assessment and reporting of all MRI scans is performed according to a standard operating procedure and is registered in the patient file by the radiologist.

    Time frame: Directly after induction chemotherapy

  7. Radiological response after chemoradiotherapy.

    Assessment and reporting of all MRI scans is performed according to a standard operating procedure and is registered in the patient file by the radiologist.

    Time frame: 6-8 weeks after chemoradiotherapy

  8. Pathologic response

    The pathologic response is graded according to the Mandard grading system. The Mandard grading is registered by the pathologist in the pathology report in the patient's medical file.

    Time frame: Directly after surgery

  9. Toxicity related to induction therapy.

    Systemic related toxicity is graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Toxicity caused by induction therapy will be scored from day one of the first cycle of induction therapy until one month after the last administration of the induction therapy and is registered in the patient's medical file by the treating medical oncologist. Only all non-hematologic NCI-CTCAE grade 3-4 and all NCI-CTCAE ≥4 are registered.

    Time frame: During induction chemotherapy

  10. The induction therapy compliance rate.

    Information on completion of induction therapy is registered by the treating medical oncologist. In all patients in whom a dose reduction is required the reason for dose reduction will be recorded in the patient's medical file.

    Time frame: During induction chemotherapy

  11. Toxicity of chemoradiotherapy.

    Chemoradiotherapy related toxicity is graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Toxicity caused by chemoradiotherapy will be scored from start of radiotherapy until 3 months after the last administration of the radiotherapy and is registered in the patient's medical file by the treating radiation oncologist. Only all non-hematologic NCI-CTCAE grade 3-4 and all NCI-CTCAE ≥4 are registered.

    Time frame: During chemoradiotherapy

  12. The compliance rate related to chemoradiotherapy.

    Information on completion of chemoradiotherapy is registered by the treating radiation oncologist and registered in the patient's medical file. In all patients in whom a dose reduction is required the reason for dose reduction will be recorded in the patient's medical file.

    Time frame: During chemoradiotherapy

  13. Number of patients undergoing surgery.

    This is calculated as a percentage from the total number of patients that were included.

    Time frame: immediately after surgery

  14. Type of surgery, including the use of intra-operative radiotherapy.

    Directly after surgery, information with respect to procedure related characteristics is registered in the surgical report in the patient's medical file by the operating surgeon. Data on intra-operative radiotherapy, if administered, are registered in the patient's medical file by the treating radiation oncologist.

    Time frame: During the surgical procedure

  15. Major surgical morbidity rate

    Surgical complications are graded according to the Clavien-Dindo grading system. Complications will be scored up to 3 months after surgery and are registered in the patient file by the treating physician.

    Time frame: During admission for surgery.

  16. Generic and cancer-specific Quality of life (QoL) assessments during treatment using Quality of life Questionnaires (QLQ)

    Generic and cancer-specific quality of life assessments are assessed with QLQ-C30, a 4 point scale. Higher scores correspond with a higher response level.

    Time frame: At the moment of inclusion, after 3 months and after 12 months.

  17. Generic and cancer-specific Quality of life (QoL) assessments during treatment

    Generic and cancer-specific quality of life assessments are assessed with QLQ-CR29, a 4 point scale. Higher scores represent better functioning on functional scales and a higher level of symptoms on the symptom scale.

    Time frame: At the moment of inclusion, after 3 months and after 12 months.

  18. Generic and cancer-specific Quality of life (QoL) assessments during treatment

    Generic and cancer-specific quality of life assessments are assessed with EQ-5D-5L, a 5 point scale. Higher scores corresponds with a higher level of symptoms on the symptom scale.

    Time frame: At the moment of inclusion, after 3 months and after 12 months.

  19. Costs

    For the purpose of economic evaluation, the EQ-5D-5L questionnaire is used at inclusion and at 3 and 12 months post-operatively. The questionnaires will be sent either by mail or digitally, according to the patient's preference.

    Time frame: At the moment of inclusion, after 3 months and after 12 months.

07

Study locations

13 sites
08

References and documents

Publications

  • van den Berg K, Schaap DP, Voogt ELK, Buffart TE, Verheul HMW, de Groot JWB, Verhoef C, Melenhorst J, Roodhart JML, de Wilt JHW, van Westreenen HL, Aalbers AGJ, van 't Veer M, Marijnen CAM, Vincent J, Simkens LHJ, Peters NAJB, Berbee M, Werter IM, Snaebjornsson P, Peulen HMU, van Lijnschoten IG, Roef MJ, Nieuwenhuijzen GAP, Bloemen JG, Willems JMWE, Creemers GJM, Nederend J, Rutten HJT, Burger JWA. Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT). BMC Cancer. 2022 Sep 6;22(1):957. doi: 10.1186/s12885-022-09947-w. PubMed 36068495 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Aug 2026, 56 months.

Of 229 non-industry phase 2 interventional studies under Rectal Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 80. This study's 56 months is above that.

Counting every sponsor, half of 243 studies reached it within 46 months; a quarter within 31 and three quarters within 75.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: start Jun 2021 → Nov 2021, primary completion Jun 2025 → Aug 2026 and completion Jun 2026 → Aug 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2021
First posted
Apr 9, 2021
StartActual
Nov 3, 2021was Jun 2021
Primary completionActual
Aug 1, 2026was Jun 2025
CompletionEst.
Aug 1, 2031was Jun 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Oct 23, 2026
Sites
8 sites added, 2 sites removed
Show 8 added (8 Netherlands)
  • Catharina Hospital Eindhoven · Eindhoven, Netherlands
  • Netherlands Cancer Institute · Amsterdam, Netherlands
  • Amsterdam UMC, location VUmc · Amsterdam, Netherlands
  • Anna Hospital · Geldrop, Netherlands
  • Elkerliek Hospital · Helmond, Netherlands
  • Maastro Clinic · Maastricht, Netherlands
  • Maxima Medical Centre · Veldhoven, Netherlands
  • St. Jans Gasthuis · Weert, Netherlands
Show 2 removed
  • Catharina Hospital Eindhoven · Eindhoven, Netherlands
  • Netherlands Cancer Institute · Amsterdam, Netherlands
Oct 23, 2026
Start date
Jun 1, 2021→Nov 3, 2021 (actual)
Oct 23, 2026
Primary completion
Jun 1, 2025→Aug 1, 2026 (actual)
Oct 23, 2026
Study completion
Jun 1, 2026→Aug 1, 2031
Oct 23, 2026
Eligibility
4 inclusion criteria edited, 1 added; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • AddedFit for (modified dose) triple chemotherapy (FOLFOXIRI)
  • EditedLower border of the tumour located on or below the sigmoidal take-off as established on MRI of the pelvis.
  • EditedConfirmed high-risk locally advanced rectal cancer, at high risk of treatment failure, meeting one of the following imaging based criteria:
  • EditedThe presence of Extramesorectalbilateral extramesorectal lymph nodes with a short-axis size >≥ 7mm (LNNLLN) or extensive LLN involving pelvic side wall structures, at high risk of an incomplete resection.
  • EditedExpected gross incomplete resection with overt tumour remaining in the patient after resection, tumour invasion in the neuroforamina, encasement of the ischiadic nerve and invasion of the cortex from S3S2 and upwards are considered not resectable • Written informed consent.
Exclusion criteria
  • ChangedBefore Radiotherapy in the pelvic area within the past 6 months.Now Previous radiotherapy in the pelvic area precluding chemoradiotherapy with a dose of 50 - 50.4 Gy.
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Not yet recruiting→Active, not recruiting
    8 sites added, 2 sites removed
    Show 8 added (8 Netherlands)
    • Catharina Hospital Eindhoven · Eindhoven, Netherlands
    • Netherlands Cancer Institute · Amsterdam, Netherlands
    • Amsterdam UMC, location VUmc · Amsterdam, Netherlands
    • Anna Hospital · Geldrop, Netherlands
    • Elkerliek Hospital · Helmond, Netherlands
    • Maastro Clinic · Maastricht, Netherlands
    • Maxima Medical Centre · Veldhoven, Netherlands
    • St. Jans Gasthuis · Weert, Netherlands
    Show 2 removed
    • Catharina Hospital Eindhoven · Eindhoven, Netherlands
    • Netherlands Cancer Institute · Amsterdam, Netherlands
    Start date Jun 1, 2021→Nov 3, 2021 (now actual)
    Primary completion Jun 1, 2025→Aug 1, 2026 (now actual)
    Study completion Jun 1, 2026→Aug 1, 2031
    Eligibility 4 inclusion criteria edited, 1 added; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • AddedFit for (modified dose) triple chemotherapy (FOLFOXIRI)
    • EditedLower border of the tumour located on or below the sigmoidal take-off as established on MRI of the pelvis.
    • EditedConfirmed high-risk locally advanced rectal cancer, at high risk of treatment failure, meeting one of the following imaging based criteria:
    • EditedThe presence of Extramesorectalbilateral extramesorectal lymph nodes with a short-axis size >≥ 7mm (LNNLLN) or extensive LLN involving pelvic side wall structures, at high risk of an incomplete resection.
    • EditedExpected gross incomplete resection with overt tumour remaining in the patient after resection, tumour invasion in the neuroforamina, encasement of the ischiadic nerve and invasion of the cortex from S3S2 and upwards are considered not resectable • Written informed consent.
    Exclusion criteria
    • ChangedBefore Radiotherapy in the pelvic area within the past 6 months.Now Previous radiotherapy in the pelvic area precluding chemoradiotherapy with a dose of 50 - 50.4 Gy.
    + 3 other changes: verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04838496
Lead sponsor
Catharina Ziekenhuis Eindhoven
Responsible party
J. W. A. Burger (Principal investigator, Catharina Ziekenhuis Eindhoven) — Principal investigator
First posted
Apr 9, 2021
Start date
Nov 3, 2021
Primary completion
Aug 1, 2026
Completion
Aug 1, 2031 (estimated)
Last update
Oct 23, 2026

Study contacts

Jacobus W.A. Burger, MD. PhD.
principal investigator · Catharina Ziekenhuis Eindhoven

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: FOLFOXIRI protocol

Start the discussion